According to our pooled analysis, patients with larger tumor size, lymph node metastasis, or poorly differentiated tumors tend to have higher level of PD-L1 expression; these patients may benefit more from treatment targeting PD-1/PD-L1 pathway. This evidence concerns the gene PDCD1 and metastatic malignant neoplasm in the lymph nodes.